Publication of tumor marker research results: The necessity for complete and transparent reporting

Journal of Clinical Oncology

Volumn 30, Issue 34, 2012, Pages 4223-4232

  McShane, Lisa M ^a   Hayes, Daniel F ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ANALYTIC METHOD; CANCER REGISTRY; CLINICAL DECISION MAKING; COMPARATIVE EFFECTIVENESS; DATA ANALYSIS; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; MEDICAL LITERATURE; METHODOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; QUALITY CONTROL; REVIEW; RISK BENEFIT ANALYSIS; SAMPLING; SYSTEMATIC ERROR; VALIDITY; VOLUNTARY REPORTING;

HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PUBLISHING; TUMOR MARKERS, BIOLOGICAL;

EID: 84870674269     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.6858     Document Type: Review

References (83)

1. Schilsky RL: Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol 27:3725-3730, 2009
2. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
3. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
4. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12:1004-1012, 2011
5. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
6. Blanke CD, Goldberg RM, Grothey A, et al: KRAS and colorectal cancer: Ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist 16:1061-1068, 2011
7. Institute of Medicine: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, DC, The National Academies Press, 2010
8. Teutsch SM, Bradley LA, Palomaki GE, et al: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. Genet Med 11:3-14, 2009
9. Cronin M, Sangli C, Liu ML, et al: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53: 1084-1091, 2007
10. National Cancer Institute: Performance Standards Reporting Requirements for Essential Assays in Clinical Trials. http://www.cancerdiagnosis.nci.nih.gov/ scientificPrograms/pacct/assay-standards.htm
11. Dowsett M, Nielsen TO, A'Hern R, et al: Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656-1664, 2011
12. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
13. Rimsza LM, Leblanc ML, Unger JM, et al: Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112:3425-3433, 2008
14. Fu K, Weisenburger DD, Choi WW, et al: Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 26:4587-4594, 2008
15. Dunleavy K, Pittaluga S, Czuczman MS, et al: Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069-6076, 2009
16. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996
17. Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005
18. Freidlin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: Design issues. J Natl Cancer Inst 102:152-160, 2010
19. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728, 2008
20. Cardoso F, Van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008
21. Hayes DF: Targeting adjuvant chemotherapy: A good idea that needs to be proven! J Clin Oncol 30:1264-1267, 2012
22. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
23. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
24. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet 379:432-444, 2012
25. Lenzer J: FDA committee votes to withdraw bevacizumab for breast cancer. BMJ 343:d4244, 2011
26. Montero AJ, Escobar M, Lopes G, et al: Bevacizumab in the treatment of metastatic breast cancer: Friend or foe? Curr Oncol Rep 14:1-11, 2012
27. Naik AD, Petersen LA: The neglected purpose of comparative-effectiveness research. N Engl J Med 360:1929-1931, 2009
28. Lyman GH, Hirsch B: Comparative effectiveness research and genomic personalized medicine. Personalized Medicine 7:223-227, 2010
29. Congressional Budget Office: Research on the comparative effectiveness of medical treatments: Issues and options for an expanded federal role. Washington, DC, Congressional Budget Office, 2007
30. Institute of Medicine: Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC, National Academies Press, 2012
31. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
32. Keedy VL, Temin S, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121-2127, 2011
33. Simon R, Altman DG: Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69:979-985, 1994
34. Altman DG: Suboptimal analysis using 'optimal'cutpoints. Br J Cancer 78:556-557, 1998
35. Altman DG, Lyman GH: Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52:289-303, 1998
36. Pepe MS, Etzioni R, Feng Z, et al: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054-1061, 2001
37. Moskowitz CS, Pepe MS: Quantifying and comparing the accuracy of binary biomarkers when predicting a failure time outcome. Stat Med 23:1555-1570, 2004
38. Song X, Pepe MS: Evaluating markers for selecting a patient's treatment. Biometrics 60:874-883, 2004
39. Altman DG, Riley RD: Primer: An evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2:466-472, 2005
40. Simon R: Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 97:866-867, 2005
41. Simon R: Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332-7341, 2005
42. Dwan K, Altman DG, Arnaiz JA, et al: Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 3:e3081, 2008
43. McShane LM, Altman DG, Sauerbrei W: Identification of clinically useful cancer prognostic factors: What are we missing? J Natl Cancer Inst 97:1023-1025, 2005
44. Kyzas PA, Denaxa-Kyza D, Ioannidis JP: Quality of reporting of cancer prognostic marker studies: Association with reported prognostic effect. J Natl Cancer Inst 99:236-243, 2007
45. Ioannidis JP, Khoury MJ: Improving validation practices in "omics" research. Science 334:1230-1232, 2011
46. Song F, Parekh S, Hooper L, et al: Dissemination and publication of research findings: An updated review of related biases. Health Technol Assess 14:iii, ix-xi, 1-193, 2010
47. Kyzas PA, Loizou KT, Ioannidis JP: Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97:1043-1055, 2005
48. Altman DG, McShane LM, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. BMC Med 10:51, 2012
49. Altman DG, McShane LM, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. PLoS Med 9:e1001216, 2012
50. Altman DG, Moher D, Schulz KF: Improving the reporting of randomized trials: The CONSORT statement and beyond. Stat Med (in press)
51. Stuart-Harris R, Caldas C, Pinder SE, et al: Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17:323-334, 2008
52. Henry NL, Hayes DF: Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11:541-552, 2006
53. Mallett S, Timmer A, Sauerbrei W, et al: Reporting of prognostic studies of tumour markers: A review of published articles in relation to REMARK guidelines. Br J Cancer 102:173-180, 2010
54. Malats N, Bustos A, Nascimento CM, et al: P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 6:678-686, 2005
55. Kyzas PA, Denaxa-Kyza D, Ioannidis JP: Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43:2559-2579, 2007
56. McCray AT, Ide NC: Design and implementation of a national clinical trials registry. J Am Med Inform Assoc 7:313-323, 2000
57. De Angelis C, Drazen JM, Frizelle FA, et al: Clinical trial registration: A statement from the International Committee of Medical Journal Editors. N Engl J Med 351:1250-1251, 2004
58. Ross JS, Mulvey GK, Hines EM, et al: Trial publication after registration in ClinicalTrials.gov: A cross-sectional analysis. PLoS Med 6:e1000144, 2009
59. Andre F, McShane LM, Michiels S, et al: Biomarker studies: A call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 8:171-176, 2011
60. BiomarkersStudiesRegistry:Homepage.http://win.biomarkerregistry.org
61. Equator Network: Resource centre for good reporting of health research studies. http://www.equator-network.org
62. [No authors listed]: Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature: Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature. Ann Intern Med 121:894-895, 1994
63. [No authors listed]: A proposal for structured reporting of randomized controlled trials: The Standards of Reporting Trials Group. JAMA 272:1926-1931, 1994
64. Begg C, Cho M, Eastwood S, et al: Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 276:637-639, 1996
65. Consolidated Standards of Reporting Trials (CONSORT): CONSORT Statement home page for transparent reporting of trials. http://www.consort-statement.org
66. Moher D, Jones A, Lepage L: Use of the CONSORT statement and quality of reports of randomized trials: A comparative before-and-after evaluation. JAMA 285:1992-1995, 2001
67. Moher D, Schulz KF, Altman D: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285:1987-1991, 2001
68. Moher D, Schulz KF, Altman DG: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191-1194, 2001
69. Moher D, Schulz KF, Altman DG: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134:657-662, 2001
70. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152:726-732, 2010
71. Altman DG, Schulz KF, Moher D, et al: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134:663-694, 2001
72. Moore HM, Kelly AB, Jewell SD, et al: Biospecimen reporting for improved study quality (BRISQ). J Proteome Res 10:3429-3438, 2011
73. Moore HM, Kelly AB, Jewell SD, et al: Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol 119:92-101, 2011
74. Moore HM, Kelly A, Jewell SD, et al: Biospecimen reporting for improved study quality. Biopreserv Biobank 9:57-70, 2011
75. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
76. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184, 2005
77. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387-391, 2005
78. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2:416-422, 2005
79. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 41:1690-1696, 2005
80. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235, 2006
81. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). Exp Oncol 28:99-105, 2006
82. American Society of Clinical Oncology: Journal of Clinical Oncology Information for Contributors: Manuscript Submission Requirements - Biomarker Submissions (REMARK Guidelines). http://jco.ascopubs.org/site/ifc/requirements. xhtml
83. Equator Network: Reporting recommendations fortumourmarkerprognostic studies(REMARK). http://www.equator-network.org/resource-centre/library-of- health-research-reporting/reporting-guidelines/remark